ASCO GUIDELINES Bundle

Metastatic Non-castrate Prostate Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475479

Contents of this Issue

Navigation

Page 3 of 3

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at GuidelineCentral.com Copyright © 2018 All rights reserved ASCONCPC1833b Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncology Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/ genitourinary-cancer-guidelines. Copyright © 2018 by American Society of Clinical Oncology. All rights reserved. Abbreviations AAP, abiraterone with prednisone or prednisolone; ADT, androgen deprivation therapy; CHAARTED, Chemohormonal Androgen Ablation Randomized Trial; LATITUDE, A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation erapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC); mCRPC, metastatic castration-resistant prostate cancer; STAMPEDE, Systemic erapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy Source Morris MJ et al. Optimizing anti-cancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncolog y Clinical Practice Guideline. J Clin Oncol. 2018 April 2; doi: 10.1200/JCO.2018.78.0619. [Epub ahead of print] ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, frequently asked questions, and other clinical tools and resources, is available at www.asco.org/genitourinary-cancer-guidelines Recommendation Grading Type Evidence Quality Strength of Recommendation EB Evidence-based H High Strong I Intermediate Moderate IC Informal Consensus L Low Weak Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Metastatic Non-castrate Prostate Cancer